Trinity Biotech (TRIB) said Tuesday it has received approval for the offshored and outsourced upstream manufacturing activities of its high-volume TrinScreen HIV rapid test from the World Health Organization.
The approval allows Trinity Biotech to transfer upstream production from in-house operations to a more cost-effective and scalable outsourced model, the company said.
The transition to an outsourced model is expected to deliver "substantial improvements" in gross margin and working capital, as part of a broader plan to streamline operations and reduce fixed costs, Trinity Biotech said.
The company's shares were up 29% in premarket activity on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.